Reference health
Role of Heart Rate Reduction in the Prevention of Experimental Heart Failure
49/49 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 49 checked references that resolve
resolves10.1056/NEJM199904223401601
Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989
resolves10.1016/S0002-9149(99)00635-9
Elevated systolic blood pressure as a cardiovascular risk factor
resolves10.1093/eurheartj/ehn575
Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis
resolves10.1016/j.amjcard.2010.02.031
Do Calcium Channel Blockers Increase the Diagnosis of Heart Failure in Patients With Hypertension?
resolves10.1016/j.jacc.2008.05.057
Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension
resolves10.1001/jama.1996.03530430051039
Reversal of Left Ventricular Hypertrophy in Essential Hypertension
resolves10.1016/S0002-9343(03)00158-X
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
resolves10.1093/eurheartj/ehi190
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
resolves10.1016/S0140-6736(08)61171-X
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
resolves10.1016/S0140-6736(10)61259-7
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
resolves10.1016/S0140-6736(08)61170-8
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
resolves10.1016/S0140-6736(10)61198-1
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
resolves10.2165/00003495-200464160-00003
Heart Rate Lowering by Specific and Selective If Current Inhibition with Ivabradine
resolves10.1159/000073933
A Single Intravenous Dose of Ivabradine, a Novel I<sub>f</sub> Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction
resolves10.1016/S0022-3565(24)29238-7
Effects of Heart Rate Reduction with Ivabradine on Exercise-Induced Myocardial Ischemia and Stunning
resolves10.1111/j.1476-5381.1996.tb15505.x
Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells
resolves10.1152/ajpheart.01337.2008
Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy
resolves10.1016/j.yjmcc.2010.05.005
Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy
resolves10.1161/hypertensionaha.109.137885
Syndecan-1 Amplifies Angiotensin II–Induced Cardiac Fibrosis
resolves10.2337/db08-0329
Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy
resolves10.1161/01.str.0000217386.37107.be
Endogenous Expression of C-Reactive Protein Is Increased in Active (Ulcerated Noncomplicated) Human Carotid Artery Plaques
resolves10.2144/05385MT01
Validation of Oligonucleotide Microarray Data Using Microfluidic Low-Density Arrays: a New Statistical Method to Normalize Real-Time RT-PCR Data
resolves10.1016/j.ejheart.2008.01.004
Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in Mice
resolves10.1161/circulationaha.107.714147
Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction
resolves10.2337/db06-1163
Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy
resolves10.1093/eurjhf/hfn043
Inflammation as a Therapeutic Target in Heart Failure? A Scientific Statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
resolves10.1159/000218178
Transcriptional Control of Pacemaker Channel Genes <i>HCN2</i> and <i>HCN4</i> by Sp1 and Implications in Re-expression of These Genes in Hypertrophied Myocytes
resolves10.1016/S0009-9236(98)90153-9
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers*
resolves10.1159/000322905
Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis
resolves10.1152/ajpheart.00564.2002
Contributions of heart rate and contractility to myocardial oxygen balance during exercise
resolves10.1152/ajpheart.00547.2001
Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise
resolves10.1093/eurheartj/ehm030
Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning
resolves10.1016/S0022-3565(25)12114-9
Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs.
resolves10.1097/00005344-200311000-00016
Anti-Ischemic Effects of Ivabradine, a Selective Heart Rate-Reducing Agent, in Exercise-Induced Myocardial Ischemia in Pigs
resolves10.1038/sj.bjp.0706996
Heart rate reduction by inhibition of I<sub><i>f</i></sub> or by β‐blockade has different effects on postsystolic wall thickening
resolves10.1161/01.CIR.94.3.340
Negative Chronotropic Effect of β-Blockade Therapy Reduces Myocardial Oxygen Expenditure for Nonmechanical Work
resolves10.1161/01.CIR.86.2.513
Effective arterial elastance as index of arterial vascular load in humans.
resolves10.1016/S1937-6448(10)82004-0
New Insights into the Mechanism of Fibroblast to Myofibroblast Transformation and Associated Pathologies
resolves10.1007/s00395-010-0147-7
Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab
resolves10.1146/annurev.pharmtox.45.120403.095802
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
resolves10.1093/eurheartj/ehn337
Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction
The 1 reference without a DOI — listed, not checked
no DOI — not checkedLorell BH. Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin II: current concepts. Basic Res Cardiol. 1992;87(suppl 2);163–172.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1161/hypertensionaha.111.183913"><img src="https://citestamp.com/citestamped/10.1161/hypertensionaha.111.183913/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1161/hypertensionaha.111.183913)